60 likes | 199 Views
RnRMarketResearch.com Adds “Dementia - Pipeline Review, H2 2015” which provides an overview of the Dementia pipeline
E N D
Dementia - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 21-Oct-2015 No. of pages: 202 Single User License: US $2000 Browse more Reports on Diseases & treatment at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Dementia - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Dementia - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: Adamas Pharmaceuticals, Inc., Addex Therapeutics Ltd, Alector LLC, AlzProtect SAS, Apceth GmbH & Co. KG, BioArctic Neuroscience AB, Biogen, Inc., Biotie Therapies Corp., Chase Pharmaceuticals Corporation, Chronos Therapeutics Limited, Daewoong Pharmaceutical Co., Ltd., Eisai Co., Ltd., FORUM Pharmaceuticals Inc., H. Lundbeck A/S, Hyundai Pharmaceutical Co., Ltd., Ildong Pharmaceutical Co., Ltd., IMMD Inc., ImStar Therapeutics Inc., Integrative Research Laboratories Sweden AB, Intellect Neurosciences, Inc., Intra-Cellular Therapies and more.. Drugs Profile Discussed in this Research: Antisense Oligonucleotides to Inhibit microRNA for Neurology, Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia, APC-621, aripiprazole, AVCRI-104P3, AZP-2006, BAN-0805, brexpiprazole, CB-2233, CB-8411, choline alfoscerate SR, CPC-201, CPC-252, D-217, dehydroevodiamine hydrochloride, dipraglurant IR, Drugs for Dementia, Drugs to Agonize c-MET for Dementia, Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment, DWJ-1365, E-2609, encenicline hydrochloride, FRM-0334, GIBH-130, Gln-1062, GTC-6000, gugulipid, HOB-075, IIPP-1, IMD-4482, IRL-752, ITI-007, KR-12, LUAF-20513, MM-201, Monoclonal Antibodies for Dementia and Alzheimer's Disease, Monoclonal Antibodies to Inhibit Tau for CNS Disorders, NAT, Neurostem, NI-205, NI-308, NNC-269100, OG-635 and more.. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Dementia - Pipeline Review, H2 2015 Scope For Dementia - Pipeline Review, H2 2015 • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Dementia - Pipeline Review, H2 2015 Reasons to Buy: • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Dementia • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Dementia - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441